



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Elexacaftor

Item No. 35307

CAS Registry No.: 2216712-66-0
Formal Name: N-[(1,3-dimethyl-1H-pyrazol-4-yl) sulfonyl]-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]-3-pyridinecarboxamide
Synonym: VX-445
MF: C₂₆H₃₄F₃N₇O₄S
FW: 597.7
Purity: ≥98%
UV/Vis.: λ_{max}: 279, 350 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Elexacaftor is supplied as a solid. A stock solution may be made by dissolving the elexacaftor in the solvent of choice, which should be purged with an inert gas. Elexacaftor is soluble in DMSO.

Description

Elexacaftor is a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) bearing the F508 deletion (F508del) mutation, which is carried by 90% of cystic fibrosis patients, and a CFTR potentiator.^{1,2} It increases CFTR levels in bronchial epithelial cells isolated from patients with F508del-CFTR mutations when used at a concentration of 2 μM.¹ Elexacaftor potentiates the transepithelial current in primary human nasal epithelial cells (EC₅₀ = 1.5 nM).² Formulations containing elexacaftor in combination with ivacaftor and tezacaftor have been used in the treatment of cystic fibrosis in patients carrying one or more mutations in the CFTR gene.

References

1. Keating, D.J., Marigowda, G., Burr, L.E., et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. *N. Engl. J. Med.* **379**(17), 1612-1620 (2018).
2. Shaughnessy, C.A., Zeitlin, P.L., and Bratcher, P.E. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. *Sci. Rep.* **11**(1), 19810 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM